Altered micafungin pharmacokinetics in intensive care unit patients

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4403-4409

  Lempers, Vincent J ^a,b   Schouten, Jeroen A ^c   Hunfeld, Nicole G ^d   Colbers, Angela ^a,b   Van Leeuwen, Henk J ^e   Burger, David M ^a,b   Verweij, Paul E ^a,b   Pickkers, Peter ^a   Brüggemann, Roger J ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE; MICAFUNGIN;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HALF LIFE TIME; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MALE; MIDDLE AGED; MULTICENTER STUDY; MYCOSES; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CRITICAL CARE; DRUG ADMINISTRATION SCHEDULE; ECHINOCANDINS; FEMALE; HALF-LIFE; HUMANS; INTENSIVE CARE UNITS; LIPOPEPTIDES; MALE; MIDDLE AGED; MYCOSES; YOUNG ADULT;

EID: 84939839306     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00623-15     Document Type: Article

References (41)

1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, EPIC II Group Investigators. 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323-2329. http://dx.doi.org/10.1001/jama.2009.1754.
2. Kett DH, Azoulay E, Echeverria PM, Vincent JL, Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. 2011. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 39:665-670. http://dx.doi.org/10.1097/CCM.0b013e318206c1ca.
3. Prowle JR, Echeverri JE, Ligabo EV, Sherry N, Taori GC, Crozier TM, Hart GK, Korman TM, Mayall BC, Johnson PD, Bellomo R. 2011. Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. Crit Care 15:R100. http://dx.doi.org/10.1186/cc10114.
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309-317. http://dx.doi.org/10.1086/421946.
5. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. 2012. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):S19-S37. http://dx.doi.org/10.1111/1469-0691.12039.
6. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535. http://dx.doi.org/10.1086/596757.
7. Matsumoto S, Wakai Y, Nakai T, Hatano K, Ushitani T, Ikeda F, Tawara S, Goto T, Matsumoto F, Kuwahara S. 2000. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 44:619-621. http://dx.doi.org/10.1128/AAC.44.3.619-621.2000.
8. Mikamo H, Sato Y, Tamaya T. 2000. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 46:485-487. http://dx.doi.org/10.1093/jac/46.3.485.
9. Petraitis V, Petraitiene R, Groll AH, Roussillon K, Hemmings M, Lyman CA, Sein T, Bacher J, Bekersky I, Walsh TJ. 2002. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 46:1857-1869. http://dx.doi.org/10.1128/AAC.46.6.1857-1869.2002.
10. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, Goto T, Tomishima M, Ohki H, Yamada A, Kawabata K, Takasugi H, Sakane K, Tanaka H, Matsumoto F, Kuwahara S. 2000. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44:57-62. http://dx.doi.org/10.1128/AAC.44.1.57-62.2000.
11. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA, Micafungin Invasive Candidiasis Working Group. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519-1527. http://dx.doi.org/10.1016/S0140-6736(07)60605-9.
12. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45:883-893. http://dx.doi.org/10.1086/520980.
13. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL, International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. 2014. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498-509. http://dx.doi.org/10.1016/S1473-3099(14)70036-2.
14. Sinnollareddy MG, Roberts JA, Lipman J, Akova M, Bassetti M, De Waele JJ, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Dimopoulos G, DALI Study Authors. 2015. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients study. Crit Care 19:33. http://dx.doi.org/10.1186/s13054-015-0758-3.
15. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. 2011. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 50:99-110. http://dx.doi.org/10.2165/11539220-000000000-00000.
16. van Wanrooy MJ, Rodgers MG, Uges DR, Arends JP, Zijlstra JG, van der Werf TS, Kosterink JG, Alffenaar JW. 2014. Low but sufficient anidulafungin exposure in critically ill patients. Antimicrob Agents Chemother 58:304-308. http://dx.doi.org/10.1128/AAC.01607-13.
17. Tabata K, Katashima M, Kawamura A, Kagayama A, Kohno S. 2006. Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis. Eur J Drug Metab Pharmacokinet 31:123-128. http://dx.doi.org/10.1007/BF03191129.
18. European Medicines Agency. 2014. Summary of product characteristics. EMA, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000734/WC500031075.pdf.
19. Hiemenz J, Cagnoni P, Simpson D, Devine S, Chao N, Keirns J, Lau W, Facklam D, Buell D. 2005. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 49:1331-1336. http://dx.doi.org/10.1128/AAC.49.4.1331-1336.2005.
20. Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I. 2005. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 45:1145-1152. http://dx.doi.org/10.1177/0091270005279580.
21. Hirata K, Aoyama T, Matsumoto Y, Ogawa F, Yamazaki H, Kikuti A, Yamamoto Y. 2007. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi 127:897-901. http://dx.doi.org/10.1248/yakushi.127.897.
22. Maseda E, Grau S, Villagran MJ, Hernandez-Gancedo C, Lopez-Tofiño A, Roberts JA, Aguilar L, Luque S, Sevillano D, Gimenez MJ, Gilsanz F. 2014. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. J Antimicrob Chemother 69:1624-1632. http://dx.doi.org/10.1093/jac/dku013.
23. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. 1996. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49:1373-1379. http://dx.doi.org/10.1016/S0895-4356(96)00236-3.
24. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. 2005. Quantification of lean bodyweight. Clin Pharmacokinet 44:1051-1065. http://dx.doi.org/10.2165/00003088-200544100-00004.
25. Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J, Bekersky I. 2005. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45:1018-1024. http://dx.doi.org/10.1177/0091270005279274.
26. Hebert MF, Townsend RW, Austin S, Balan G, Blough DK, Buell D, Keirns J, Bekersky I. 2005. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45:954-960. http://dx.doi.org/10.1177/0091270005278601.
27. Undre N, Pretorius B, Stevenson P. 3 June 2014. Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction. Eur J Drug Metab Pharmacokinet. http://dx.doi.org/10.1007/s13318-014-0204-y.
28. Undre NA, Stevenson P, Kuse ER, Demeyer D. 2012. Pharmacokinetics of micafungin in adult patients with invasive candidiasis and candidemia. Open J Med Microbiol 2:84-90. http://dx.doi.org/10.4236/ojmm.2012.23012.
29. Muilwijk EW, Schouten JA, van Leeuwen HJ, van Zanten AR, de Lange DW, Colbers A, Verweij PE, Burger DM, Pickkers P, Bruggemann RJ. 2014. Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother 69:3294-3299. http://dx.doi.org/10.1093/jac/dku313.
30. Speight TM, Holford NH. 1997. Avery's drug treatment, 4th ed. Wiley- Blackwell, Hoboken, NJ.
31. Nguyen TH, Hoppe-Tichy T, Geiss HK, Rastall AC, Swoboda S, Schmidt J, Weigand MA. 2007. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 60:100-106. http://dx.doi.org/10.1093/jac/dkm125.
32. Hope WW, Kaibara A, Roy M, Arrieta A, Azie N, Kovanda LL, Benjamin DK, Jr. 2015. Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents. Antimicrob Agents Chemother 59:905-913. http://dx.doi.org/10.1128/AAC.03736-14.
33. Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. 2008. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis 60:329-331. http://dx.doi.org/10.1016/j.diagmicrobio.2007.09.018.
34. Pasipanodya J, Hall RG, Jr, Gumbo T. 2015. In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos. Clin Pharmacol Ther 97:292-297. http://dx.doi.org/10.1002/cpt.38.
35. Keirns J, Sawamoto T, Holum M, Buell D, Wisemandle W, Alak A. 2007. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother 51:787-790. http://dx.doi.org/10.1128/AAC.00673-06.
36. Oshima K, Kanda Y, Kako S, Ohno K, Kishino S, Kurokawa M. 2013. Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 15:323-327. http://dx.doi.org/10.1111/tid.12070.
37. Kishino S, Ohno K, Shimamura T, Furukawatodo H. 2004. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transplant 18:676-680. http://dx.doi.org/10.1111/j.1399-0012.2004.00272.x.
38. Gumbo T, Drusano GL, Liu W, Kulawy RW, Fregeau C, Hsu V, Louie A. 2007. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 51:968-974. http://dx.doi.org/10.1128/AAC.01337-06.
39. Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J. 2008. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 52:3497-3503. http://dx.doi.org/10.1128/AAC.00478-08.
40. Andes D, Ambrose PG, Hammel JP, Van Wart SA, Iyer V, Reynolds DK, Buell DN, Kovanda LL, Bhavnani SM. 2011. Use of pharmacokineticpharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob Agents Chemother 55:2113-2121. http://dx.doi.org/10.1128/AAC.01430-10.
41. Sirohi B, Powles RL, Chopra R, Russell N, Byrne JL, Prentice HG, Potter M, Koblinger S. 2006. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 38:47-51. http://dx.doi.org/10.1038/sj.bmt.1705398.